To systematically evaluate the clinical efficacy and safety of Yinhuang oral preparations in the treatment of acute upper respiratory infection and provide evidence-based references for clinical treatment of acute upper respiratory infection.Methods:The databases,such as CJFD,CSPD,CCD,CBM,Embase,PubMed,and Cochrane Library,were systematically searched for randomized controlled trials(RCTs) on Yinhuang oral preparations in treating acute upper respiratory infarction,and the included RCTs underwent quality evaluation and data extraction.Review Manager 5.3 was used for Meta-analysis,and descriptive analysis was carried out for RCTs that could not be combined.Results:Ten RCTs were included,with 2 165 involved.The Meta-analysis showed that compared with the conditions in the control group,Yinhuang oral preparations could improve clinical total effective rate［RR=1.22,95%CI(1.10 to 1.34),P<0.000 1］,relieve sore throat［RR=1.44,95%CI(0.76 to 2.72),P=0.27］,and shorten duration time of cough,fever,and sore throat［MD=-0.83,95%CI(-1.30 to -0.36),P=0.000 5; MD=-1.40,95%CI(-2.07 to -0.72),P<0.000 1; MD=-0.94,95%CI(-1.07 to -0.81),P<0.000 01］.There was no statistical difference in the adverse events between the two groups.Conclusion:Yinhuang oral preparations had a significant curative effect in the treatment of acute upper respiratory infection without increasing the incidence of adverse events.The efficacy,however,needs to be confirmed by more high-quality trials.